Ambry Genetics®
A Konica Minolta Company

Tumor Test Requisition Form - Page 1 of 3

COMPLETE ENTIRE FORM AND SUBMIT PEDIGREE/CLINIC NOTES/PATHOLOGY REPORT TO AVOID DELAYS

PATIENT INFORMATION

Name (Last, First, MI)	Biological Sex ☐F ☐M	Date of Birth (MM/DD/YY)	MRN

Ethnicity: ☐African American ☐Asian ☐Caucasian ☐Hispanic ☐Portuguese ☐Other: | Ashkenazi Jewish ☐Yes ☐No

Address	City	State	Zip

Preferred Method Of Contact	Phone	Email	Preferred Billing
☐Phone ☐Text (requires mobile phone number) ☐Email			☐Insurance ☐Self-pay ☐Institutional

SPECIMEN INFORMATION

Both normal sample (e.g. blood or saliva) and tumor tissue required. Detailed specimen requirements can be found at ambrygen.com/specimen-requirements

Blood/saliva	Collection Date:	Specimen ID #:
Tumor	Please fill out the "Tumor Specimen Intended for Testing" section on page 2.	

Specimen Collection Options: ☐Phlebotomy draw ☐Insurance preverification first ☐Send blood kit to patient* ☐Send saliva kit to patient

** As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.*

PATHOLOGY INFORMATION (REQUIRED) ☐ Please retrieve specimen

Pathology report for relevant tumor tissue specimen is REQUIRED for processing. Please include a copy when order is submitted. Tumor specimen will be returned after testing is completed.

Institution Name	Pathologist	Phone	Fax

Address	City	State	Zip

ORDERING LICENSED PROVIDER/SENDING FACILITY

Facility Name (Facility Code)	Address	City	State /Country	Zip	Phone

Ordering Licensed Provider Name (Last, First)(Code)	NPI#	Phone	Fax/Email

ADDITIONAL RESULTS RECIPIENTS

Genetic Counselor or Other Medical Provider Name (Last, First) (Code)	Phone/Fax/Email

Other Medical Provider Name (Last, First) (Code)	Phone/Fax/Email

CONFIRMATION OF INFORMED CONSENT, PRE-TEST GENETIC COUNSELING, AND MEDICAL NECESSITY FOR GENETIC TESTING

The undersigned person (or representative thereof) ensures he/she is a licensed medical professional authorized to order genetic testing and confirms that the patient has given appropriate consent. I confirm that testing is medically necessary and that test results may impact medical management for the patient. I agree to allow Ambry Genetics to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider. Furthermore, all information on this TRF is true to the best of my knowledge. My signature applies to the attached letter of medical necessity.

Signature Required for Processing Medical Professional Signature: Date:

☐ INSURANCE BILLING (Include copy of both sides of insurance card)

Patient Relation to Policy Holder? ☐Self ☐Spouse ☐Child	Name and DOB of Policy Holder (if not self)	
Insurance Company	Policy #	HMO Auth #

Out Of Pocket (OOP):
We will start testing immediately, unless you check the box below. We will attempt to contact the patient if the estimated out-of-pocket costs are > USD $100.

☐ Do not start testing until my patient approves payment terms regarding estimated out-of-pocket costs
By checking this box, I understand that there will be a delay in starting this test until Ambry is able to reach the patient to communicate OOP costs.

Special Billing Notes:

☐ INSTITUTIONAL BILLING

Facility Name ☐ *Send invoice to facility address above*

Address

Contact Name

Phone Number	E-mail/Fax

☐ PATIENT PAYMENT

☐Check (Payable to Ambry Genetics)
☐Credit Card (Call 949-900-5795)

Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetics Corporation (Ambry), authorize Ambry to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending Ambry money received from my health insurance company.
For patient payment by credit card: I hereby authorize Ambry Genetics Corporation to bill my credit card as indicated above. In order to expedite consideration for eligibility for **Ambry's Patient Assistance Program**, please provide the total annual gross household income: $_____ and the number of family members in the household supported by the listed income: _____. I authorize Ambry Genetics Corporation to verify the above information for the sole purpose of assessing financial need, including the right to seek supporting documentation.

FOR NY RESIDENTS:

☐ I am a New York resident and I give Ambry Genetics permission to store my sample for longer than 60 days. **NOTE:** If left blank, consent is interpreted as "NO".

Signature Required For Insurance/Self-Pay Patients and NY Sample Storage Consent: Date:

Ambry Genetics®
A Konica Minolta Company

Patient Name: _____ DOB: _____

Tumor Test Requisition Form - Page 2 of 3

PLEASE SUBMIT THE FOLLOWING WITH THE TRF:
1. Clinic Notes 2. Pedigree 3. Insurance Card 4. Pathology Report

PATIENT CLINICAL HISTORY (Please indicate if diagnosis is active)

☐ No personal history of cancer ☐ History of allogenic bone marrow or peripheral stem cell transplant** | ICD-10 code(s):

Cancer/Tumor	Active	Age at Dx	Pathology and Other Info
Breast	☐		Type: ER☐(+) ☐(-) ☐unk PR☐(+) ☐(-) ☐unk HER2/neu☐(+) ☐(-) ☐unk
Colorectal	☐		Location:
Uterine	☐		
Ovarian	☐		☐ Fallopian tube ☐ Primary peritoneal
Prostate	☐		Gleason Score: Metastatic: ☐Y ☐N
Other Cancer	☐		Type:

Other clinical history:

***Blood or saliva from patients with active/recent hematological disease or a history of allogenic bone marrow or stem cell transplant should not be used for genetic testing. For these patients, an alternative specimen (e.g. cultured fibroblasts) is recommended. See ambrygen.com for details.*

PATIENT GENETIC TESTING HISTORY

Lynch syndrome tests only: This section must be completed for Medicare beneficiaries

☐ No previous molecular and/or genetic testing

Genetic testing Test(s) performed:_____

Result(s):_____

Please include copies of any previous genetic test results.

Microsatellite instability analysis:
☐ Stable (MSS) ☐ Unstable/high (MSI-H) ☐ Unstable/low (MSI-L)

IHC, if multiple primaries, tumor used:_____
☐ Proteins present: _____ ☐ Proteins absent: _____

☐ Tissue is unavailable or insufficient for IHC/MSI testing

FAMILY HISTORY^

^Completing this section is not mandatory for ordering if a pedigree and/or clinical note with family history is supplied, but is recommended and helps with results interpretation and claims filing.

☐ None (maternal) ☐ None (paternal) ☐ Maternal history unknown ☐ Paternal history unknown

Relation to patient	Maternal	Paternal	Cancer/Polyp Type	Dx age	Relation to patient	Maternal	Paternal	Cancer/Polyp Type	Dx age
	☐	☐				☐	☐		
	☐	☐				☐	☐		
	☐	☐				☐	☐		

TESTS REQUESTED

Check to order	Test Name	Test Code	Tumor Specimen Intended for Testing: Specimen & Block ID	Primary Tumor Type/Site	Metastatic Site, *if applicable*††
Both normal sample (e.g. blood or saliva) and tumor tissue are required. Please see specimen preparation instruction sheet for more detailed specimen requirements.					
☐	Lynch syndrome paired testing^^	8982			
☐	TumorNext®-*Lynch*^^	8980			
☐	TumorNext-*Lynch* plus ColoNext®^^	8981			
☐	TumorNext-*Lynch* plus BRCANext-*Expanded*™^^	8985			
☐	TumorNext-*Lynch* plus CancerNext®^^	8984			
☐	Add on *BRAF* (V600E), *KRAS*, and *NRAS* targeted analysis *(This can only be applied to test options above.)*				
☐	Microsatellite instability (MSI) analysis^^,†	8702			
☐	*MLH1* promoter hypermethylation analysis^^	7978			
☐	TumorNext-*BRCA*†	9810			
☐	TumorNext-*HRD*†	9811			
☐	TumorNext-*HRD* plus BRCANext-*Expanded*†	9814			
☐	TumorNext-*HRD* plus CancerNext†	9813			

^^Lynch syndrome tumors will be accepted. Visit ambrygen.com for more details.
†Ovarian tumors (including Fallopian tube and primary peritoneal) will be accepted. For other cancer types, please discuss with your Ambry Account Manager.
††Please indicate the organ the tumor metastasized to from the original primary tumor site.

Will the course of treatment change depending upon the results of the test? ☐Yes ☐No

For assistance regarding requested tumor samples, please call 949.900.5783.

Notes:

For complete gene lists or additional test information, please visit ambrygen.com

Ambry Genetics®
A Konica Minolta Company

Patient Name: _____ DOB: _____

Supplemental Information - Page 3 of 3

Test Name	Test Code	Description
Lynch syndrome paired testing	8982	Paired tumor and germline testing of *MLH1, MSH2, MSH6, PMS2, + EPCAM* del/dup
TumorNext-*Lynch*	8980	Paired tumor and germline testing of *MLH1, MSH2, MSH6, PMS2*, and *EPCAM*; microsatellite instability (MSI) and *MLH1* promoter hypermethylation analysis
TumorNext-*Lynch* plus ColoNext	8981	TumorNext-*Lynch* (described above) plus germline analysis of *APC, AXIN2, BMPR1A, CDH1, CHEK2, GREM1, MSH3, MUTYH, NTHL1, POLD1, POLE, PTEN, SMAD4, STK11,* and *TP53*
TumorNext-*Lynch* plus BRCANext-*Expanded*	8985	TumorNext-*Lynch* (described above) plus germline analysis of *ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, RECQL, SMARCA4, STK11,* and *TP53*
TumorNext-*Lynch* plus CancerNext	8984	TumorNext-*Lynch* (described above) plus germline analysis of *AXIN2, APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, GREM1, HOXB13, MSH3, MUTYH, NBN, NF1, NTHL1, PALB2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, SMARCA4, STK11,* and *TP53*
TumorNext-*BRCA*	9810	Paired tumor and germline analysis of *BRCA1* and *BRCA2*
TumorNext-*HRD*	9811	Paired tumor and germline analysis of *BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK2, MRE11A, NBN, PALB2, RAD51C,* and *RAD51D*
TumorNext-*HRD* plus BRCANext-*Expanded*	9814	TumorNext-*HRD* (described above) plus germline analysis of *CDH1, DICER1, EPCAM, MLH1, MSH2, MSH6, NF1, PMS2, PTEN, RECQL, SMARCA4, STK11,* and *TP53*
TumorNext-*HRD* plus CancerNext	9813	TumorNext-*HRD* (described above) plus germline analysis of *APC, AXIN2, BMPR1A, CDH1, CDK4, CDKN2A, DICER1, EPCAM, GREM1, HOXB13, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NTHL1, PMS2, POLD1, POLE, PTEN, RECQL, SMAD4, SMARCA4, STK11,* and *TP53*

7 Argonaut, Aliso Viejo, CA 92656 USA Toll Free +1.866.262.7943 Fax +1.949.900.5501 ambrygen.com